MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Отворен

1.22

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.21

Максимум

1.22

Ключови измерители
By Trading Economics
Приходи	17M -26M
Служители	171
EBITDA	19M -23M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+147.93% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-27M 76M
Предишно отваряне	1.22
Предишно затваряне	1.22

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.43 / 1.6 Подкрепа & съпротива

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

31.12.2025 г., 22:20 ч. UTC

Значими двигатели на пазара

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31.12.2025 г., 17:31 ч. UTC

Значими двигатели на пазара

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31.12.2025 г., 16:30 ч. UTC

Значими двигатели на пазара

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31.12.2025 г., 15:19 ч. UTC

Значими двигатели на пазара

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31.12.2025 г., 15:17 ч. UTC

Значими двигатели на пазара

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31.12.2025 г., 14:37 ч. UTC

Значими двигатели на пазара

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

31.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

31.12.2025 г., 21:13 ч. UTC

Придобивния, сливания и поглъщания

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31.12.2025 г., 20:40 ч. UTC

Пазарно говорене

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31.12.2025 г., 20:22 ч. UTC

Пазарно говорене

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31.12.2025 г., 19:50 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31.12.2025 г., 19:31 ч. UTC

Пазарно говорене

Precious Metals Cap Off Record Runs -- Market Talk

31.12.2025 г., 18:50 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

31.12.2025 г., 18:50 ч. UTC

Пазарно говорене

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31.12.2025 г., 17:17 ч. UTC

Пазарно говорене

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31.12.2025 г., 17:16 ч. UTC

Значими двигатели на пазара

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31.12.2025 г., 17:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

31.12.2025 г., 17:00 ч. UTC

Придобивния, сливания и поглъщания

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31.12.2025 г., 15:57 ч. UTC

Придобивния, сливания и поглъщания

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31.12.2025 г., 15:54 ч. UTC

Пазарно говорене

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31.12.2025 г., 15:02 ч. UTC

Значими двигатели на пазара

Nike Shares Rise After CEO Hill Buys $1M of Shares

31.12.2025 г., 14:40 ч. UTC

Придобивния, сливания и поглъщания

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31.12.2025 г., 14:20 ч. UTC

Пазарно говорене

Crude Futures On Track to End the Year With Losses -- Market Talk

31.12.2025 г., 13:46 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

31.12.2025 г., 13:01 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

31.12.2025 г., 11:10 ч. UTC

Пазарно говорене

Copper Remains in Touching Distance of Record Highs -- Market Talk

31.12.2025 г., 10:46 ч. UTC

Пазарно говорене

Euro on Track For Strong Annual Performance -- Market Talk

31.12.2025 г., 10:25 ч. UTC

Пазарно говорене

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

31.12.2025 г., 10:23 ч. UTC

Пазарно говорене

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

31.12.2025 г., 09:33 ч. UTC

Пазарно говорене

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

147.93% нагоре

12-месечна прогноза

Среден 3 USD 147.93%

Висок 4 USD

Нисък 2 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.